Danaher Corporation First Quarter 2026 Financial Results and Form 10-Q

These documents primarily consist of a quarterly financial report (Form 10-Q) filed with the Securities and Exchange Commission for the period ending March 27, 2026. The records detail the financial performance and operational health of Danaher Corporation, showcasing growth in net earnings and sales across its biotechnology, life sciences, and diagnostics segments. A significant highlight includes the company's $9.9 billion definitive agreement to acquire Masimo Corporation, a specialty diagnostics provider. The sources also outline the firm's debt structure, tax obligations, and the establishment of a $5.0 billion credit facility to support future liquidity and acquisition funding. Additionally, the initial text includes a brief security verification notice from the financial website MarketBeat.